Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

FDA gives tentative approval to a low-cost generic HIV prevention injection

Close-up of vaccines, syringe, and stethoscope on a reflective surface in a clinical setting.

The U.S. Food and Drug Administration has granted tentative approval to Dr. Reddy’s Laboratories for a generic version of lenacapavir, the twice-yearly injectable medicine used to prevent HIV infection.

The decision is seen as a key step toward wider access in low- and middle-income countries, where the generic is expected to cost about 40 US dollars per person per year — comparable to daily preventive tablets. The brand-name product is marketed by Gilead Sciences.

Source: STAT News